Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

NervGen Pharma Corp. (V:NGEN)

Business Focus: Biotechnology & Medical Research

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for NGEN within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 13, 2020 10:53 ET
NervGen Pharma Responds to Recent Increase in Market Activity
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2020) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, confirms that the Company's management is unaware of any undisclosed information or material change in the Company's operations that would account for the recent increase in market activity.
Read full article
Nov 27, 2019 08:00 ET
NervGen Pharma Appoints Paul Brennan as President & Chief Executive Officer
Lloyd Mackenzie Appointed to the New Position of Chief Operating Officer
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
16.69
10.56
Price to Book - most recent quarter
13.44
3.16
2.07
Price to Cash Flow per share - TTM
--
31.32
12.29
Price to Free Cash Flow per share - TTM
--
1.27
18.54
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 31, 202013,966-94,081
Jan 15, 2020108,04777,483
Dec 31, 201930,564708
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

NervGen Pharma Corp. is a Canada-based regenerative medicine company that is focused on the development of therapeutics for the treatment of nerve damage, including spinal cord injuries (SCI) and peripheral nerve injuries (PNI). The Company also identifies, evaluates and develops other drug candidates for other medical conditions arising from nerve damage.

See business summary

Twitter

Search (past week) for $NGEN.CA NGEN.V